Virtual Library
Start Your Search
Mihyun Kim
Author of
-
+
P14 - Immuno-biology and Novel Immunotherapeutics (Phase I and Translational) - Immuno-Biology (ID 153)
- Event: WCLC 2020
- Type: Posters
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
- Presentations: 1
- Moderators:
- Coordinates: 1/28/2021, 00:00 - 00:00, ePoster Hall
-
+
P14.28 - Association Between the Type of First-Line Chemotherapy and Outcome of Second-Line Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer (ID 3778)
00:00 - 00:00 | Presenting Author(s): Mihyun Kim
- Abstract
Introduction
The immune checkpoint inhibitors that target the programmed cell death receptor-1 and its ligand have achieved remarkable success in treatment for advanced lung cancer. However, it is little known about clinical biomarkers that could help to select patients who will respond well to immunotherapy. We conducted a retrospective study to figure out whether the first-line platinum-based doublet chemotherapy agent would affect the subsequent outcome of immunotherapy in non-small cell lung cancer (NSCLC) patients.
Methods
Retrospective data of 108 NSCLC patients who were treated with immunotherapy including pembrolizumab, nivolumab, or atezolizumab between January 2018 and June 2020 were reviewed. We excluded patients who did not receive platinum-based doublet chemotherapy agents as first-line and patients who received immunotherapy as other than the second line. The clinical information, pathological variables, and radiological findings were reviewed. The patient data were followed up until the date of the last visit, death, or the end of data recording (31 June 2020). The Kaplan-Meier method was used for estimation of survival time and the log-rank test was used for assessment of the difference in survival between the types of first-line chemotherapy.
Results
A total of 84 NSCLC patients were treated with second-line immune checkpoint inhibitors after first-line platinum-based doublet chemotherapy. Forty-three (51%), 36 (43%), 3 (4%) and 2 (2%) patients received pemetrexed, gemcitabine, docetaxel and paclitaxel for the first-line treatment, respectively. The pemetrexed group showed significantly shorter mean progression-free survival (4.0 months vs. 9.1 months, P=0.036) compared to other regimen groups. The gemcitabine group showed longer survival than other groups (8.4 months vs. 4.6 months and 37.3 months vs. 32.0 months for PFS and OS, respectively); however, this difference was not statistically significant (P=0.158 and P=0.112 for PFS and OS, respectively).
Conclusion
The type of platinum-based doublet chemotherapy received as first-line treatment may predict the survival of patients treated with second-line immune checkpoint inhibitors.
